Lucid Diagnostics Inc.
LUCD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 104,027.3% | 40.5% | -30.8% | – |
| Cost of Goods Sold | $2 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -40.1% | -53.5% | -87.3% | -79.2% |
| R&D Expenses | $1 | $0 | $0 | $0 |
| G&A Expenses | $6 | $6 | $0 | $0 |
| SG&A Expenses | $10 | $10 | $0 | $0 |
| Sales & Mktg Exp. | $4 | $4 | $0 | $0 |
| Other Operating Expenses | $0 | -$10 | $0 | $0 |
| Operating Expenses | $11 | $0 | $0 | $0 |
| Operating Income | -$12 | -$0 | -$0 | -$0 |
| % Margin | -971% | -978.8% | -1,508.1% | -1,033.8% |
| Other Income/Exp. Net | $1 | $0 | -$0 | $0 |
| Pre-Tax Income | -$10 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10 | -$0 | -$0 | -$0 |
| % Margin | -858.5% | -381.7% | -3,249.8% | -964.2% |
| EPS | -0.1 | -0.08 | -0.52 | -0.2 |
| % Growth | -25.5% | 84.7% | -160% | – |
| EPS Diluted | -0.1 | -0.08 | -0.52 | -0.2 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10 | -$0 | -$0 | -$0 |
| % Margin | -822% | -362.1% | -3,222% | -945% |